Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Brain Behav Immun. 2012 May 26;26(6):988–995. doi: 10.1016/j.bbi.2012.05.011

Table 4.

Nonserious adverse events reported by at least one study subject during trial.

Placebo (n=46) 1.25 g/d n-3 (n=46) 2.5 g/d n-3 (n=46) p-value
Ear ache 6 (13%) 4 (9%) 2 (4%) 0.39
Sore throat 3 (7%) 10 (22%) 8 (17%) 0.10
Swollen glands 1 (2%) 0 (0%) 1 (2%) 1.00
Stuffy nose 18 (39%) 20 (43%) 23 (50%) 0.60
Wheeze 3 (7%) 1 (2%) 2 (4%) 0.87
Dry cough 10 (22%) 10 (22%) 6 (13%) 0.50
Wet cough 8 (17%) 6 (13%) 6 (13%) 0.87
Nausea 7 (15%) 6 (7%) 8 (17%) 0.28
Stomach pain 12 (26%) 13 (28%) 14 (30%) 0.97
Diarrhea 10 (22%) 7 (15%) 12 (26%) 0.48
Other symptoms 25 (54%) 25 (54%) 23 (50%) 0.93

Data are n (%).